Intraoperative Open-Cavity Implant for Accelerated Partial Breast Irradiation Using High-Dose Rate Multicatheter Brachytherapy in Japanese Breast Cancer Patients: A Single-Institution Registry Study

Kazuhiko Sato, Yoshio Mizuno, Masahiro Kato, Takahiro Shimo, Jun Kubota, Naoko Takeda, Yuko Inoue, Hiroshi Seto, Tomohiko Okawa

Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Tokyo, Japan.
Department of Radiation Oncology, Tokyo-West Tokushukai Hospital, Tokyo, Japan.
Health Evaluation Center, Utsunomiya Memorial Hospital, Tochigi, Japan.
Inoue Ladies Clinic, Tokyo, Japan.
Seto Hospital, Saitama, Japan.

DOI: 10.4236/jct.2012.325104                

Abstract

Background: Previous research has compared the efficacies of accelerated partial breast irradiation (APBI) and wholebreast irradiation (WBI). APBI immediately after surgery may provide more benefit after intraoperative insertion of catheters. Although balloon catheter-based APBI is available in the US, it is difficult in Japanese women, who have relatively small breasts. With the applicators being implanted during tumor removal, APBI can be started immediately after surgery. The aim of this study was to assess the safety and efficacy of APBI using the intraoperative open-cavity implant technique. Method: Patients (age≥40 years) with invasive breast cancer (diameter≤3 cm) were enrolled. Before lumpectomy, the insertion of applicators and delivery doses were simulated by computed tomography (CT). After confirmation of free margins and negative sentinel nodes (SNs) using frozen section analysis, applicators were inserted. Postoperative CT-based dose distribution analysis was performed using dose-volume histograms. APBI was started on the day of surgery, delivering 32 Gy in 8 fractions over the following 5-6 days, and it covered a distance of 2 cm from tumor margins. This observational study was approved by the institutional review board of our hospital. Results: From October 2008 to July 2012, 157 women (160 lesions) were enrolled (age 55.0 years, <40:9, SN+: 25, for patients’ request). The mean number of applicators used was 6.4 (2-15) and mean planning target volume was 35.8 cm3 (6.5-137.1 cm3). All radiotherapy-related toxicities were mild. However, 12 patients (7.5%) experienced wound breakdown because of surgical site infection. Two patients developed ipsilateral breast tumor recurrence (1 marginal, 1 at a distant site). Conclusions: Despite the small number of participants and a short follow-up period, our results suggest that this technique could be helpful in establishing clinical safety and efficacy.

Keywords

Breast Cancer; Partial Breast Irradiation; Multicatheter Brachytherapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	B. Fisher, S. Anderson, J. Bryant, et al., “Twenty-Year Follow-Up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer,” The New England Journal of Medicine, Vol. 347, 2002, pp. 1233-1241. doi:10.1056/NEJMoa022152
[2]	U. Veronesi, N. Cascinelli, L. Mariani, et al., “Twenty-Year Follow-Up of a Randomized Study Comparing Breast-Conserving Surgerywith Radical Mastectomy for Early Breast Cancer,” The New England Journal of Medicine, Vol. 347, 2002, pp. 1227-1232. doi:10.1056/NEJMoa020989
[3]	V. Vinh-Hung and C. Verschraegen, “Breast-Conserving Surgery with or without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality,” Journal of the National Cancer Institute, Vol. 96, No. 2, 2004, pp. 115-1121. doi:10.1093/jnci/djh013
[4]	M. Clarke, R. Collins, S. Darby, et al., “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” Lancet, Vol. 366, No. 9503, 2005, pp. 2087-2106.
[5]	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), S. Darby, P. McGale, C. Correa, et al., “Effect of Radiotherapy after Breast-Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials,” Lancet, Vol. 378, No. 9804, 2011, pp. 1707-1716. doi:10.1016/S0140-6736(11)61629-2
[6]	D. C. Farrow, W. C. Hunt and J. M. Samet, “Geographic Variation in the Treatment of Localized Breast Cancer,” The New England Journal of Medicine, Vol. 326, 1992, pp. 1097-1101. doi:10.1056/NEJM199204233261701
[7]	D. A. Lazovich, E. White, D. B. Thomas, et al., “Underutilization of Breast-Conserving Surgery and Radiation Therapy among Women with Stage I or II Breast Cancer,” The Journal of the American Medical Association, Vol. 266, No. 24, 1991, pp. 3433-3438. doi:10.1001/jama.1991.03470240055032
[8]	B. A. Mann, J. M. Samet, W. C. Hunt, et al., “Changing Treatment of Breast Cancer in New Mexico from 1969 through 1985,” The Journal of the American Medical Association, Vol. 259, No. 23, 1988, pp. 3413-3417. doi:10.1001/jama.1988.03720230023024
[9]	R. Ballard-Barbash, A. L. Potosky, L. C. Harlan, et al., “Factors Associated with Surgical and Radiation Therapy for Early Stage Breast Cancer in Older Women,” Journal of the National Cancer Institute, Vol. 88, No. 11, 1996, pp. 716-726. doi:10.1093/jnci/88.11.716
[10]	W. F. Athas, M. Adams-Cameron, W. C. Hunt, et al., “Travel Distance to Radiation Therapy and Receipt Of Radiotherapy following Breast-Conserving Surgery,” Journal of the National Cancer Institute, Vol. 92, No. 3, 2000, pp. 269-271. doi:10.1093/jnci/92.3.269
[11]	A. T. Schroen, D. R. Brenin, M. D. Kelly, et al., “Impact of Patient Distance to Radiation Therapy on Mastectomy Use in Early-Stage Breast Cancer Patients,” Journal of Clinical Oncology, Vol. 23, No. 28, 2005, pp. 7074-7080. doi:10.1200/JCO.2005.06.032
[12]	B. Fisher and S. Anderson, “Conservative Surgery for the Management of Invasive and Noninvasive Carcinoma of the Breast: NSABP Trials,” National Surgical Adjuvant Breast and Bowel Project,” World Journal of Surgery, Vol. 18, No. 1, 1994, pp. 63-69. doi:10.1007/BF00348193
[13]	K. Holli, R. Saaristo, J. Isola, et al., “Lumpectomy with or without Postoperative Radiotherapy for Breast Cancer with Favourable Prognostic Features: Results of a Randomized Study,” British Journal of Cancer, Vol. 84, No. 2, 2001, pp. 164-169. doi:10.1054/bjoc.2000.1571
[14]	The Uppsala-Orebro Breast Cancer Study Group, “Sector Resection with or without Postoperative Radiotherapy for Stage I Breast Cancer: A Randomized Trial,” Journal of the National Cancer Institute, Vol. 82, No. 23, 1990, p. 1851. doi:10.1093/jnci/82.23.1851
[15]	R. M. Clark, P. B. McCulloch, M. N. Levine, et al., “Randomized clinical Trial to Assess the Effectiveness of Breast Irradiation following Lumpectomy and Axillary Dissection for Node-Negative Breast Cancer,” Journal of the National Cancer Institute, Vol. 84, No. 9, 1992, pp. 683-689. doi:10.1093/jnci/84.9.683
[16]	G. L. Smith, Y. Xu, T. A. Buchholz, et al., “Brachytherapy for Accelerated Partial-Breast Irradiation: A Rapidly Emerging Technology in Breast Cancer Care,” Journal of Clinical Oncology, Vol. 29, No. 2, 2010, pp. 157-165. doi:10.1200/JCO.2009.27.0942
[17]	V. Zannis, P. Beitsch, F. Vicini, et al., “Descriptions and Outcomes of Insertion Techniques of a Breast Brachytherapy Balloon Catheter in 1403 Patients Enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial,” The American Journal of Surgery, Vol. 190, No. 4, 2005, pp. 530-538. doi:10.1016/j.amjsurg.2005.06.007
[18]	G. L. Smith, Y. Xu, T. A. Buchholz, et al., “Association between Treatment with Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival among Older Women with Invasive Breast Cancer,” The Journal of the American Medical Association, Vol. 307, No. 17, 2012, pp. 1827-1837. doi:10.1001/jama.2012.3481
[19]	Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications /docs/ctcaev3.pdf
[20]	M. Trombetta, T. B. Julian, Y. Kim, et al., “The Allegheny General Modification of the Harvard Breast Cosmesis Scale for the Retreated Breast,” Oncology, Vol. 23, No. 11, 2009, pp. 954-956.
[21]	B. K. Mary, “Dramatic Increase in the Use of Implantable Accelerated Partial Breast Irradiation after Breast-Conserving Surgery,” CA: A Cancer Journal for Clinicians, Vol. 61, No. 4, 2011, pp. 205-206. doi:10.3322/caac.20122
[22]	B. Belletti, J. S. Vaidya, S. D’Andrea, et al., “Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation And Invasion Caused by Surgical Wounding,” Clinical Cancer Research, Vol. 14, No. 5, 2008, pp. 1325-1332. doi:10.1158/1078-0432.CCR-07-4453
[23]	J. Huang, L. Barbera, M. Brouwers, et al., “Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review,” Journal of Clinical Oncology, Vol. 21, No. 3, 2003, pp. 555-563. doi:10.1200/JCO.2003.04.171
[24]	R. S. Punglia, A. M. Saito, B. A. Neville, et al., “Impact of Interval from Breast Conserving Surgery to Radiotherapy on Local Recurrence in Older Women with Breast Cancer: Retrospective Cohort Analysis,” British Medical Journal, Vol. 340, 2010, p. 845. doi:10.1136/bmj.c845
[25]	U. Kraus-Tiefenbacher, L. Bauer, A. Scheda, et al., “Long-Term Toxicity of an Intraoperative Radiotherapy Boost Using Low Energy X-Rays during Breast-Conserving Surgery,” International Journal of Radiation Oncology, Biology and Physics, Vol. 66, No. 2, 2006, pp. 377-381. doi:10.1016/j.ijrobp.2006.05.042
[26]	M. C. Leonardi, G. B. Ivaldi, L. Santoro, et al., “Long-Term Side Effects and Cosmetic Outcome in a Pool of Breast Cancer Patients Treated with Intraoperative Radiotherapy with Electrons as Sole Treatment,” Tumori, Vol. 98, No. 3, 2012, pp. 324-330.
[27]	E Sperk, G Welzel, A Keller, et al., “Late Radiation Toxicity after Intraoperative Radiotherapy (IORT) for Breast Cancer: Results from the Randomized Phase III Trial TARGIT A,” Breast Cancer Research and Treatment, Vol. 135, No. 1, 2012, pp. 253-256. doi:10.1007/s10549-012-2168-4
[28]	H. M. Kuerer, T. B. Julian, E. A. Strom, et al., “Accelerated Partial Breast Irradiation after Conservative Surgery for Breast Cancer,” Annals of Surgery, Vol. 239, No. 3, 2004, pp. 338-351. doi:10.1097/01.sla.0000114219.71899.13
[29]	J. S. Vaidya, D. J. Joseph, J. S. Tobias, et al., “Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A trial): An International, Prospective, Randomised, Non-Inferiority Phase 3 Trial,” Lancet, Vol. 376, No. 9735, 2010, pp. 91-102. doi:10.1016/S0140-6736(10)60837-9
[30]	A. Ruano-Ravina, P. Cantero-Mu?oz and A. Eraso Urién, “Efficacy and Safety of Intraoperative Radiotherapy in Breast Cancer: A Systematic Review,” Cancer Letters, Vol. 313, No. 1, 2011, pp. 15-25. doi:10.1016/j.canlet.2011.08.020
[31]	Z. Póti, C. Nemeskéri, A. Fekésházy, et al., “Partial Breast Irradiation with Interstitial 60CO Brachytherapy Results in Frequent Grade 3 or 4 Toxicity. Evidence Based on a 12-Year Follow-Up of 70 Patients,” International Journal of Radiation Oncology, Biology and Physics, Vol. 58, No. 4, 2004, pp. 1022-1033. doi:10.1016/j.ijrobp.2003.08.013
[32]	F. Perera, F. Chisela, L. Stitt, et al., “TLD Skin Dose Measurements and Acute and Late Effects after Lumpectomy and High-Dose-Rate Brachytherapy Only for Early Breast Cancer,” International Journal of Radiation Oncology, Biology and Physics, Vol. 62, No. 5, 2005, pp. 1283-1290. doi:10.1016/j.ijrobp.2005.01.007
[33]	S. M. Bentzen and J. R. Yarnold, “Reports of Unexpected Late Side Effects of Accelerated Partial Breast Irradiation—Radiobiological Considerations,” International Journal of Radiation Oncology, Biology and Physics, Vol. 77, No. 4, 2010, pp. 969-973. doi:10.1016/j.ijrobp.2010.01.059
[34]	T. Saphner, D. C. Tormey and R. Gray, “Annual Hazard Rates of Recurrence for Breast Cancer after Primary Therapy,” Journal of Clinical Oncology, Vol. 14, No. 10, 1996, pp. 2738-2746.
[35]	H. A. Jones, N. Antonini, A. A. Hart, et al., “Impact of Pathological Characteristics on Local Relapse after Breast-Conserving Therapy: A Subgroup Analysis of the EORTC Boost versus No Boost Trial,” Journal of Clinical Oncology, Vol. 27, No. 30, 2009, pp. 4939-4947. doi:10.1200/JCO.2008.21.5764
[36]	M. Sanghani, P. T. Truong, R. A. Raad, et al., “Validation of a Web-Based Predictive Nomogram for Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy,” Journal of Clinical Oncology, Vol. 28, No. 5, 2010, pp. 718-722. doi:10.1200/JCO.2009.22.6662
[37]	C. Aristei, C. Leonardi, F. Stracci, et al., “Risk Factors for Relapse after Conservative Treatment in T1-T2 Breast Cancer with One to Three Positive Axillary Nodes: Results of an Observational Study,” Annals of Oncology, Vol. 22, No. 4, 2011, pp. 842-847. doi:10.1093/annonc/mdq470
[38]	C. Shah, J. B. Wilkinson, M. Lyden, et al., “Predictors of Local Recurrence following Accelerated Partial Breast Irradiation: A Pooled Analysis,” International Journal of Radiation Oncology, Biology and Physics, Vol. 82, No. 5, 2012, pp. 825-830. doi:10.1016/j.ijrobp.2011.11.042
[39]	P. L. Nguyen, A. G. Taghian, M. S. Katz, et al., “Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated with Local and Distant Recurrence after Breast-Conserving Therapy,” Journal of Clinical Oncology, Vol. 26, No. 14, 2008, pp. 2373-2378. doi:10.1200/JCO.2007.14.4287
[40]	E. K. Millar, P. H. Graham, S. A. O’Toole, et al., “Prediction of Local Recurrence, Distant Metastases, and Death after Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel,” Journal of Clinical Oncology, Vol. 27, No. 28, 2009, pp. 4701-4708. doi:10.1200/JCO.2008.21.7075
[41]	Z. Gabos, J. Thoms, S. Ghosh, et al., “The Association between Biological Subtype and Locoregional Recurrence in Newly Diagnosed Breast Cancer,” Breast Cancer Research and Treatment, Vol. 124, No. 1, 2010, pp. 187-194. doi:10.1007/s10549-010-1135-1
[42]	J. A. Hattangadi-Gluth, J. Y. Wo, P. L. Nguyen, et al., “Basal Subtype of Invasive Breast Cancer Is Associated with a Higher Risk of True Recurrence after Conventional Breast-Conserving Therapy,” International Journal of Radiation Oncology, Biology and Physics, Vol. 82, No. 3, 2012, pp. 1185-1191. doi:10.1016/j.ijrobp.2011.02.061